Haleon (NYSE:HLN) Price Target Increased to $10.95 by Analysts at Morgan Stanley

Haleon (NYSE:HLN - Get Free Report) had its price target raised by stock analysts at Morgan Stanley from $9.90 to $10.95 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Morgan Stanley's price target suggests a potential upside of 4.09% from the stock's current price.

Other analysts also recently issued research reports about the company. Berenberg Bank assumed coverage on Haleon in a research note on Tuesday, August 6th. They set a "buy" rating on the stock. The Goldman Sachs Group lowered Haleon from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $10.95.

Haleon Stock Performance

Shares of Haleon stock traded up $0.06 during midday trading on Friday, hitting $10.52. The company had a trading volume of 4,140,145 shares, compared to its average volume of 4,942,407. The company has a fifty day simple moving average of $9.73 and a 200 day simple moving average of $8.85. The stock has a market cap of $48.04 billion, a price-to-earnings ratio of 35.07, a PEG ratio of 3.10 and a beta of 0.26. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon has a 12-month low of $7.70 and a 12-month high of $10.76.

Haleon (NYSE:HLN - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. Haleon had a return on equity of 13.15% and a net margin of 9.71%. During the same quarter in the previous year, the firm posted $0.08 earnings per share. As a group, analysts predict that Haleon will post 0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haleon

Institutional investors have recently modified their holdings of the stock. Clearbridge Investments LLC raised its position in Haleon by 8.6% during the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company's stock valued at $344,888,000 after acquiring an additional 3,307,009 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Haleon by 164.6% during the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company's stock valued at $111,454,000 after purchasing an additional 8,423,475 shares in the last quarter. Sculptor Capital LP increased its holdings in shares of Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company's stock valued at $73,407,000 after purchasing an additional 3,592,000 shares in the last quarter. Douglas Lane & Associates LLC boosted its holdings in Haleon by 1.6% during the second quarter. Douglas Lane & Associates LLC now owns 8,533,768 shares of the company's stock worth $70,489,000 after buying an additional 131,892 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in Haleon by 2.7% during the second quarter. Envestnet Asset Management Inc. now owns 7,572,548 shares of the company's stock worth $62,549,000 after buying an additional 196,843 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.